MedTrace Logo

Safety Escalating Repeat IV, in Stroke Patients

NCT00833989 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-11-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.

Conditions

  • Ischaemic Attack, Transient

Interventions

DRUG

GSK249320

I.V. infusion

DRUG

PLACEBO

Placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-08
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States
  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00833989 on ClinicalTrials.gov